The global Artificial Intelligence in Drug Discovery market demonstrated a value of USD 253.8 million in 2019 and is projected to reach USD 2,127.9 million by 2027, exhibiting a remarkable compound annual growth rate (CAGR) of 31.9%. Artificial intelligence (AI) technology is increasingly being utilized to comprehend the targeted actions of new drugs and their applications in various known diseases. Numerous research institutions are embracing artificial intelligence to facilitate the discovery of novel drugs. Furthermore, advancements in machine learning techniques to effectively handle vast datasets play a pivotal role in driving advancements in drug discovery.
The future market growth is expected to be fueled by several key factors, including the growing demand for efficient treatment of chronic illnesses, the increasing incidence of epidemics/pandemics caused by emerging viruses, and the rising need for cost-efficient drug discovery. Additionally, the industry is poised for expansion due to the escalating demand for streamlining the costly and time-consuming conventional drug discovery process. Furthermore, the global demand for personalized medicine is anticipated to contribute to the industry's growth.
Get a sample of the report @ https://www.reportsanddata.com/download-free-sample/2775
Companies considered and profiled in this market study
The key players in the global Artificial Intelligence in Drug Discovery includes companies such as NVIDIA Corporation, Deep Genomics, Cloud Pharmaceuticals, IBM Corporation, Microsoft and Google, Insilico Medicine, BenevolentAI, Cyclica, BERG LLC, and Envisagenics.
To know more about the report @ https://www.reportsanddata.com/report-detail/artificial-intelligence-in-drug-discovery-market
The Artificial Intelligence in Drug Discovery Market is influenced by various driving factors and restraints.
Driving Factors:
- Enhanced Efficiency and Speed: Artificial intelligence techniques, such as machine learning and deep learning algorithms, can process and analyze vast amounts of data in a fraction of the time it would take traditional methods. This increased efficiency and speed in drug discovery processes, including target identification, lead optimization, and toxicity prediction, drive the adoption of AI in the pharmaceutical industry.
- Improved Target Identification: AI algorithms can analyze complex biological data, including genomics, proteomics, and metabolomics, to identify potential drug targets with greater precision. This enables researchers to prioritize targets that are more likely to be successful, reducing the time and resources spent on less promising avenues.
- Accelerated Drug Repurposing: AI techniques can help identify existing drugs that have the potential to be repurposed for new therapeutic indications. By analyzing large datasets, including electronic health records and scientific literature, AI can identify connections between drugs and diseases, expediting the drug discovery process.
- Cost Reduction: AI in drug discovery has the potential to reduce costs associated with research and development. By optimizing experiments, predicting outcomes, and reducing the reliance on trial-and-error approaches, AI can streamline the drug development process and minimize unnecessary expenses.
Restraints:
- Lack of Sufficient High-Quality Data: AI algorithms require access to large, high-quality datasets to generate accurate predictions and insights. However, in drug discovery, obtaining comprehensive and reliable datasets can be challenging, especially for rare diseases or novel targets. Insufficient data can limit the effectiveness of AI algorithms and hinder their application in drug discovery.
- Interpretability and Validation Challenges: AI models often operate as black boxes, making it difficult to interpret the underlying decision-making process. The lack of transparency and interpretability can raise concerns about the reliability and safety of AI-driven drug discoveries. Validating AI-generated predictions and ensuring their reproducibility is also a challenge that needs to be addressed.
- Regulatory and Ethical Considerations: The adoption of AI in drug discovery introduces regulatory and ethical considerations. The regulatory landscape needs to keep pace with the rapid advancements in AI technologies to ensure patient safety and efficacy. Ethical considerations surrounding data privacy, consent, and bias also need to be addressed to maintain public trust in AI-driven drug discovery.
- Integration into Existing Workflows: Integrating AI into existing drug discovery workflows and infrastructure can be a complex process. Overcoming technical and organizational barriers and ensuring seamless integration of AI tools and methodologies can pose challenges for companies and research institutions.
Request a customization of the report @ https://www.reportsanddata.com/request-customization-form/2775
About Us:
Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyze consumer behavior shifts across demographics, across industries and help client’s make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across a multiple industries including Healthcare, Technology, Chemicals, Power and Energy. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market.
Contact Us:
John W
(Head of Business Development)
Reports and Data | Web: www.reportsanddata.com
Direct Line: +1-212-710-1370
E-mail: sales@reportsanddata.com
Blogs | Press Release | Industry News | Our competencies
Browse More Upcoming Reports @ https://www.reportsanddata.com/upcoming-reports
Browse More Latest Reports @ https://www.reportsanddata.com/report
Browse More Reports:
